Temple Performs Nation’s First Non-Surgical Lung Volume Reduction for Patient with Severe Emphysema
Temple also recently became the first U.S. site to begin training U.S. physicians on the care and management of emphysema patients who may receive the Zephyr® Endobronchial Valve
Temple University Hospital has become the first U.S. center to perform bronchoscopic lung volume reduction using implantation of the Zephyr® Endobronchial Valve (Zephyr® EBV®) to treat severe emphysema following U.S. FDA approval.
Gerard J. Criner, MD, FACP, FACCP, Chair and Professor of Thoracic Medicine and Surgery at the Lewis Katz School of Medicine at Temple University (LKSOM) and Director of the Temple Lung Center, and his Lung Center team completed the 45-minute procedure on August 10.
“This first procedure post-FDA approval is a turning point in our capabilities to treat severe emphysema using a minimally invasive bronchoscopic option,” Dr. Criner said. “We are very excited to be able to clinically offer this therapy to patients with severe emphysema who remain symptomatic despite optimal medical care.”
Lung volume reduction surgery for treatment of emphysema is beneficial but can be invasive and risky in some. The Zephyr® EBV® now provides an alternative option for patients with emphysema and suffering from hyperinflation. The Zephyr® EBV® is placed using a bronchoscope and flexible delivery catheter and then functions as a one-way valve causing the damaged lobe of the lung to deflate, while preventing further lobar inflation. This reduces hyperinflation, which happens when air becomes trapped in the lungs and makes breathing difficult for emphysema patients.
The FDA granted pre-market approval to the Zephyr® EBV® on June 29 under its breakthrough devices designation. This approval followed a study published in May by Dr. Criner and a Temple University Hospital-led research team that found the implantation of the Zephyr® EBV® successfully reduced shortness of breath and improved lung function and quality of life, with benefits lasting at least one year post-intervention for patients with severe emphysema. That clinical trial was known as LIBERATE.
In the LIBERATE trial, which included 190 patients, almost half of the patients treated with Zephyr® EBV® experienced improved lung function, compared with just 17 percent of patients treated with current standard medical management approaches for emphysema.
Moreover, patients who received the Zephyr® therapy continued to experience clinical benefits 12 months after receiving treatment compared to the control group. Side effects related to the intervention were considered acceptable relative to the clinical gains observed for the treated population.
Key to the success of the LIBERATE trial was proper patient selection. In LIBERATE and smaller previous trials, Zephyr® was found to be effective in patients who exhibited little to no collateral ventilation, a phenomenon in which air moves around obstructed lung tissues via channels that bypass the normal airways.
LIBERATE was funded by Pulmonx Corporation, Redwood City, California.
Editor’s Note: Neither Dr. Criner nor any member of his immediate family has financial interest in Pulmonx.